Meeting
Abstract Number: F13
SHM Converge 2022
Background: The use of metered-dose inhalers (MDIs) with spacers for delivering bronchodilator therapy is established as equivalent to the use of nebulizers (nebs) for symptom response.[1-3] Additional well-documented benefits to using MDIs in place of nebs include fewer systemic side effects, better long-term patient adherence to therapy, and, in the era of COVID-19, decreased use […]